Patent Application
20210030039
The invention relates to sweetened prebiotic compositions which have particular applications as functional food ingredients for foodstuffs and incorporation in meal replacement products or used by themselves to sweeten foods.
The global sweetener market is currently dominated by sugar and is forecast to reach $112bn by 2022. There is an increasing move towards low calorie or calorie free sweeteners. A number of sweeteners, such as Steviol glycosides and Mogroside V are classified as high intensity sweeteners (HIS) and have reported sweet potencies relative to sucrose of approximately 150× and 400× respectively. However, a number of HIS are associated with bitter or off notes which reduce their appeal to consumers.
Prebiotics are substrates that are selectively utilized by host microorganisms, such as lactobacilli or bifidobacteria, conferring a health benefit, and are finding much increased application into the food sector. Prebiotics can be non-digestible food ingredients that are selectively metabolised by colonic bacteria which contribute to improved health. As such, their use can promote beneficial changes within the indigenous gut microbiota and they can help survivability of probiotics. They are distinct from most dietary fibres like pectin, celluloses, xylan, which have a global effect on gut bacterial populations and are not selectively metabolised in the gut. Criteria for classification as a prebiotic is that it must resist gastric acidity, hydrolysis by mammalian enzymes and absorption in the upper gastrointestinal tract, and it reach the colon in appropriate amount to be fermented by intestinal microbiota and selectively stimulate the growth and/or activity of intestinal bacteria associated with health and well-being.
It is an object of the present invention to provide a prebiotic composition, or a composition comprising a prebiotic component, which can impart a sweet taste. In particular, it is an object of the present invention to provide a prebiotic composition, or a composition comprising a prebiotic component, which imparts a sweet taste, with low bitter and/or an undesirable after tastes. It is a further object of the present invention to provide a prebiotic composition, or a composition comprising a prebiotic component, which is not digested in the upper gastrointestinal tract of humans or animals and can therefore be used as calorie free, or substantially calorie free, functional ingredient which can improve gut microbiome diversity.
In accordance with a first aspect of the present invention, there is provided a prebiotic composition comprising:
(i) an enzymatically modified high intensity sweetener glycoside; and
(ii) an oligosaccharide.
In accordance with a related aspect of the present invention, there is provided a prebiotic composition comprising:
(i) an enzymatically modified high intensity sweetener glycoside; and
(ii) an enzymatically synthesised oligosaccharide.
In accordance with a further related aspect of the present invention, there is provided a synthetic prebiotic composition comprising:
(i) an enzymatically modified high intensity sweetener glycoside; and
(ii) an enzymatically synthesised oligosaccharide.
The term “synthetic” and “synthesised” are intended to mean products which are not naturally occurring or produced in nature. The terms do of course encompass products which are ‘man made’ using natural products, such as naturally derived pre-cursor compositions and naturally derived enzymes.
The the high intensity sweetener glycoside may be enzymatically modified by galactosylation and/or fructosylation and/or deglycosylation.
The high intensity sweetener glycoside may be selected from one or more (or a combination) of the following: Steviol glycosides (such as Rebaudioside A) or Mogroside (such as Mogroside V), or derivatives thereof.
Preferably, the enzyme or enzymes is or are microbially derived. The enzyme or enzymes may be derived from the Aspergillus genus. The enzymes may be derived from one or more of the following species of Aspergillus: Aspergillus officinalis; Aspergillus aculeatus; Aspergillus awamori; Aspergillus carbonarius; Aspergillus cellulosae; Aspergillus oryzae; Aspergillus flavus; Aspergillus japonicas; Aspergillus nidulansl; or Aspergillus niger.
The oligosaccharides obtained may be one the following: fructooligosaccharides (FOS), galactooligosaccharides (GOS), α-galactooligosaccharides, β-glucooligosaccharides, xylooligosaccharides and combinations thereof. It is preferred that the oligosaccharides obtained are one or more of the following: galactooligosaccharides (GOS) or fructooligosaccharides (FOS).
The composition may comprise up to about 5% galactosylated and/or up to about 5% fructosylated and/or 5% deglycosylated high intensity sweetener glycoside. Preferably, the composition may comprise up to about 2% galactosylated and/or up to about 2% fructosylated and/or 2% deglycosylated high intensity sweetener glycoside. More preferably, the composition comprises up to about 1.5% galactosylated and/or up to about 1.5% fructosylated and/or 1.5% deglycosylated high intensity sweetener glycoside.
The high intensity sweetener glycoside may be galactosylated and/or fructosylated and/or deglycosylated during the oligosaccharide synthesis.
The high intensity sweetener glycoside will preferably have been galactosylated and/or fructosylated and/or deglycosylated simultaneously with the synthesis of oligosaccharides.
In one embodiment, the high intensity sweetener glycoside comprises steviol glycosides which are modified by up to about 3 units of lactose or fructose by galactosylation and/or fructosylation and/or deglycosylation. In another embodiment, the high intensity sweetener glycoside comprises steviol glycosides which are modified by up to about 4 units of lactose or fructose by galactosylation and/or fructosylation and/or deglycosylation. In an alternative embodiment, the high intensity sweetener glycoside comprises steviol glycosides which are modified by about 4 or more units of lactose or fructose by galactosylation and/or fructosylation and/or deglycosylation.
In one embodiment, the high intensity sweetener glycoside comprises mogrosides which are modified by up to about 3 units of galactose by galactosylation. In another embodiment, the high intensity sweetener glycoside comprises mogrosides which are modified by up to about 2 units of fructose by fructosylation. In an alternative embodiment, the high intensity sweetener glycoside comprises mogrosides which are modified by about 2 or more units of fructose by fructosylation.
The steviosides may comprise a mixture of steviosides having different modifications. For example, the composition comprises a mixture of one or more of: (i) rebaudioside A, rebaudioside F, rebaudioside C, rubusoside or stevioside with 1 unit of fructose; (ii) stevioside with 2 units of fructose or rebaudioside A or rebaudioside C with 1 unit of fructose; and (iii) stevioside with 2 units of fructose or rebaudioside A or rebaudioside C with 1 unit of fructose. In the alternative, the composition comprises a mixture of one or more of: (i) rebaudioside A and rebaudioside C or stevioside with 1 unit of galactose; (ii) stevioside with 2 units of galactose or rebaudioside A or rebaudioside C with 1 unit of galactose; (iii) stevioside with 3 units of galactose or rebaudioside A or rebaudioside C with 2 units of galactose; and (iv) stevioside with 4 units of galactose or rebaudioside A or rebaudioside C with 2 units of galactose.
The mogrosides may comprise a mixture of mogrosides having different modifications. For example, the mogrosides may comprise a mixture of one or more of mogroside II, mogroside III, mogrosid IV, mogroside V or mogroside VI. Alternatively, the mogrosides may comprise a mixture of one or more of: (i) mogroside V; (ii) mogrosid IV, and (iii) mogroside III. Further alternatively, the mogrosides may comprise a mixture of one or more of: (i) mogroside III; (ii) mogrosid IV; (iii) mogroside V; (iv) mogroside with 1 unit of fructose; and (v) mogroside with 2 units of fructose. Yet further, the mogrosides may comprises a mixture of: (i) mogroside IV; (ii) mogroside with 1 unit of galacose; (iii) mogroside V with 2 units of galacose; and (iv) mogroside V with 3 units of galacose.
All of the prebiotic composition aspects as described herein have been shown to advantageously form sweet natural and healthy fibres which are not digested in the human upper gastrointestinal tract and can therefore be used as calorie free, or substantially calorie free, functional ingredients. These sweet fibres have been developed as potential bulk sugar replacements as a product which has sweetness similar to sucrose but contain no, or substantially no, calories, whilst also advantageously improving microbiome diversity.
The components of the prebiotic compositions have been found to be significantly sweeter than all other samples, with the advantage of low off-flavours (e.g. bitterness, sourness, staleness, saltiness etc).
In accordance with a second aspect of the present invention, there is provided the use of the prebiotic compositions as herein above described as a low calorie or calorie free sweet prebiotic. It will be apparent to the skilled addressee that the composition may also be incorporated, or is for incorporation, in or on, a range of foodstuffs, food supplements or calorie restricted meal replacement products or used by itself to sweeten.
In certain embodiments, the composition may be in a powdered or granular form, and optionally, included in a sachet or jar so that a consumer can add the desired amount of the composition to a foodstuff.
The term “foodstuff” is intended to mean any material which can be safely ingested by a human or animal, including, but not limited to foods, beverages, cereals, bakery products, breaded and battered products, dairy products, confectionary, snacks, and meals. The term includes those products which require reconstitution prior to being cooked or eaten. The term also includes any food/nutritional supplements or medicaments (such as vitamin tablets or antibiotic liquids).
It will be apparent to the skilled addressee that the modified high intensity sweetener glycosides may be incorporated into a product, by way of blending or mixing the glycosides with other ingredients. Alternatively, the modified high intensity sweetener glycosides may be used to coat a product.
In accordance with a third aspect of the present invention, there is provided a method for producing a sweetened prebiotic composition, the method comprising:
a) contacting high intensity sweetener glycosides with one or more enzymes effective to galactosylate and/or fructosylate and/or deglycosylate the high intensity sweetener glycoside in the presence of different donors (such as sucrose and/or lactose), mainly disaccharides; and
b) obtaining the high intensity sweetener glycoside with different oligosaccharides during galactosylation and/or fructosylation and/or deglycosylation of the high intensity sweetener glycoside so as to form sweetened prebiotic composition.
The high intensity sweetener glycoside in the method may be selected from one or more of the following: Steviol glycosides (such as Rebaudioside A), or Mogroside (such as Mogroside V), or derivatives thereof. Preferably, the high intensity sweetener glycoside is be selected from one or more of the following: Steviol glycosides, or Mogroside V, or derivatives thereof.
The high intensity sweetener glycoside in the method may be galactosylated, fructosylated and/or deglycosylated using one or more enzymes selected from: β-galactosidases and multi-enzyme complexes containing a wide range of carbohydrases, including arabanase, cellulase, β-glucanase, hemicellulose, pectinases and xylanase produced by a species/strain of Aspergillus.
The oligosaccharide in the method may be synthesized and be one or more of the following: fructooligosaccharides (FOS), galactooligosaccharides (GOS), β-gluco-oligosaccharides, α-galactooligosaccharides and xylooligosaccharides and combinations thereof. It is preferred that the synthesized oligosaccharide is selected from one or more of the following galactooligosaccharides (GOS) or fructooligosaccharides (FOS).
The sweetened prebiotic composition in the method may comprise up to about 5% galactosylated and/or up to about 5% fructosylated and/or up to 5% deglycosylated high intensity sweetener glycoside. Preferably, the composition in the method may comprise up to about 2% galactosylated and/or up to about 2% fructosylated and/or 2% deglycosylated high intensity sweetener glycoside. More preferably, the composition in the method comprises up to about 1.5% galactosylated and/or up to about 1.5% fructosylated and/or 1.5% deglycosylated high intensity sweetener glycoside.
The high intensity sweetener glycoside may be galactosylated and/or fructosylated and/or deglycosylated in the presence of the enzyme and a disaccharide (donor).
The composition of the method may comprise a galactooligosaccharide or fructooligosaccharide.
The method may be employed to produce a composition as herein above described with reference to the first and second aspects of the present invention.
It will be apparent to the skilled addressee that a number of the features of the composition listed in respect to a number of the aspects of the invention will be interchangeable with the compositions and methods described unless they are incompatible.
Embodiments of the present invention will now be described, by way of examples only.
The aim of these experiments was to determine the intensity of sweetness and any off flavours of a number of oligosaccharides and enzymatically modified high intensity glycosides, obtained during the same enzymatic reaction.
This experiment sought to investigate the potential yield and preferred enzymes for producing, fructosylated and/or deglycosylated steviol glycosides and FOS during the same enzymatic reaction. The enzymes investigated were carbohydrases complexes from Aspergillus and Inulinase from Lactobacillus (R&D). The substrate was sucrose and steviol glycosides. The conditions used were 1.5% steviol glycosides, 60% sucrose, purification was by means of yeast fermentation and the drying process utilised lyophilisation and vacuum evaporation.
The best results were obtained utilising microbial enzymes complexes. The experiment suggested that the use of the commercial enzyme provided improved taste when the fructosylated and/or deglycosylated steviol glycosides was mixed with FOS generated during synthesis. The results therefore suggest that the mixture would be suitable for use as a prebiotic due to the high FOS concentration obtained during the enzymatic reaction.
This experiment sought to investigate the potential yield and preferred enzymes for producing galactosylated and/or deglycosylated steviol glycosides, and GOS during the same enzymatic reaction. The enzymes investigated were β-galactosidases from Aspergillus and Bifidobacterium bifidum. The substrates were lactose and steviol glycosides. The conditions were 1.5% steviol glycosides, 40% lactose. Purification was by means of yeast fermentation and the drying process was lyophilisation and rotovapor.
The best results were obtained by using the β-galactosidases from Aspergillus. The results show the potential for the use of commercial enzymes to produce galactosylated and/or deglycosylated steviol glycosides and GOS obtained during the synthesis. The results therefore suggest that the high GOS concentration obtained during the enzymatic syntheis would be suitable for use as a prebiotic.
This experiment sought to investigate the potential yield and preferred enzymes for producing fructosylated and/or deglycosylated mogrosides, and FOS, during the same enzymatic reaction. The enzymes investigated were carbohydrases complexes from Aspergillus acuelatus and Inulinase from Lactobacillus gasseri (R&D). The substrate was sucrose and steviol glycosides. The conditions used were 1.5% steviol glycosides, 60% sucrose, purification was by means of yeast fermentation and the drying process utilised lyophilisation and vacuum evaporation.
The best results were obtained utilising microbial enzymes complexes. The experiment suggested that the use of the commercial enzyme provided improved taste when the fructosylated and/or deglycosylated mogrosides. It is believed that this is the first report of fructosylated mogrosides. The results therefore suggest that fructosylated and/or deglycosylated mogrosides and FOS, obtained simultaneously during the enzymatic reaction, would provide a good prebiotic mainly due to the high FOS concentration.
This experiment sought to investigate the potential yield and preferred enzymes for producing during the same enzymatic reaction, galactosylated and/or deglycosylated mogrosides and GOS. The enzymes investigated were β-galactosidases from Aspergillus and Bifodabcaterium. bifidum. The substrate used was lactose and mogrosides. The conditions used were 1.5% mogrosides, 40% lactose. Purification was performed using yeast fermentation and the drying process used lyophilisation and rotovapor.
The best results were obtained with were β-galactosidases from Aspergillus. It is believed that this is the first report of galactosylated mogrosides. The results therefore suggest that galactosylated and/or deglycosylated mogrosides, mixed with GOS, obtained simultaneously during the enzymatic reaction, would provide a good prebiotic due to the high GOS concentration.
A trained sensory panel at the Reading Sensory Science Centre (UK) were employed for sensory profiling of the samples. There were 10 panellists with between 1 and 9 years' experience. A QDA (quantitative descriptive analysis) profiling approach was taken. The panel used the same vocabulary that they had developed as a consensus for the tasting sessions including the term liquorice flavour which is characteristic note of steviol glycosides. The panel were retrained at the start of the sample set over 3 separate tasting sessions. This re-training focused on ensuring that they could reliably score sweetness relative to the new concentration of sucrose standard positions.
Rating was carried out independently using unstructured lines scales (scaled 0-100), in duplicate, in isolated sensory booths. However, in order to improve discrimination for sweetness, the four sucrose samples were used as standards and the mean values for each of these samples, as agreed by the panel, are shown in Table 1 below.
At the start of each scoring session the panel tasted the four reference samples in order of increasing strength to re-familiarise themselves with the positioning of these levels of sweetness on the line scale. The reference samples (10 mL) were served in transparent polystyrene cups (30 mL). They then palate cleansed with warm filtered tap water and low salt crackers (Carr's water crackers) before commencing the sample tasting session, and again between each sample scoring session.
Samples, labelled with random 3 digit codes, were presented in a balanced presentation order in a monadic sequential manner with a maximum of 6 samples per day. Samples were served at 23-24° C. (room temperature) with air conditioning of the room set to 23° C.
The panel used 15 attributes to define samples, as shown in Table 2 below, where mean scores (0-100) for mogrosides (M) and steviol glycosides (SG) modified using two different glycosidase mixtures (F: Example 1 and 3 and G: Example 2 and 4) as shown.
28.6 c
65.8 b
91.1 a
25.5 c
15.5 b
35.3 a
33.1 a
19.1 b
14.1 a
13.2 a
12.0 a
20.2 c
43.2 b
61.8 a
12.0 c
Table 3 below shows the equivalent sucrose and relative sweetness values of the samples tested.
Experiments were conducted to assess the impact of MV-FOS, MV-GOS, SG-FOS and SG-GOS (1% w/v) on the metabolic activity of the human gut microbiome.
Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) spectra were recorded by using a Voyager DE-PRO mass spectrometer (Applied Biosystems) equipped with a nitrogen laser emitting at 337 nm with a 3 ns, and 3 Hz frequency. Ions generated by laser desorption were introduced into a time of flight analyzer (1.3 m flight path) with an acceleration voltage of 25 kV, 94% grid voltage, 0.075% ion guide wire voltage, and a delay time of 400 ns in the linear positive ion mode. Mass spectra were obtained over the m/z range 100-5000. 2,5-Dihydroxybenzoic acid (>98%, Fluka) at a concentration of 10 mg/ml in water (Milli-Q water, Millipore, Bedfor, USA) was used as matrix. Samples were diluted 1:100 in water and then, mixed with the matrix solution at a ratio of approximately 1:3. 1 μL of this solution was spotted onto a flat stainless-steel sample plate and dried in air. External mass calibration was applied using the monoisotopic [M+H]+ values of of des-Arg1 Bradykinin, Angiotensin I, Glu1-Fibrino-peptide B, ACTH (1-17), ACTH (18-39), ACTH (7-38) and Insuline (Bovine). of the Calibration Mixtures 1 and 2, Sequazyme Peptide Mass Standards Kits; Applied Biosystems.
Separation and analysis of enzymatically modified steviol glycosides and mogrosides by LC-MS was performed at 25° C. on a C18 column (150 mm×2.1 mm, 3.5 mm particle size, ThermoFisher) at a flow rate of 0.1 mL/min with a solvent gradient of acetonitrile and water (0.1% formic acid). All experiments were carried out on a Finnigan Surveyor pump with quaternary gradient system coupled to a Finnigan LCQ Deca ion trap mass spectrometer using an ESI interface. Sample injections (10 mL) were carried out by a Finnigan Surveyor autosampler. All instruments (Thermo Fisher Scientific, San Jose, Calif., USA), and data acquisition were managed by Xcalibur software (1.2 version; Thermo Fisher Scientific).
The impact of MV-FOS, MV-GOS, SG-FOS and SG-GOS (1% w/v) on the metabolic activity of the human gut microbiome was investigated in pH and temperature-controlled batch cultures. Impact on the concentration of organic acids was compared to short chain fructooligosaccharides (prebiotics positive control; FUJIFILM Wako Chemicals, Germany), and a carbohydrate negative control. Fructooligosaccharides and galactooligosaccharides produced by the activity the same enzymes used for the synthesis of modified MV and SG (1% w/v) were also tested as well as non-modified MV and SG (0.2% w/v).
Freshly voided faecal samples were obtained from five healthy adults, free from gastrointestinal disorders who had not taken antibiotics for 6 months prior to the study and prebiotics and/or probiotics for 6 weeks prior to the study.
Sterile fermenters (20 mL working volume, Soham scientific, Ely, UK) were filled with pre-reduced sterile basal media consisting of: peptone water (Oxoid, Basingstoke, UK) 2 g L−1; yeast extract (Oxoid, Basingstoke, UK) 2 g L−1; NaCl 0.1 g L−1; K2HPO4 0.04 g L−1; KH2PO4 0.04 g L−1; MgSO4.7H2O 0.01 g L−1; CaCl2.6H2O 0.01 g L−1; NaHCO3 2 g L−1; haemin 0.05 g L−1; cysteine.HCl 0.5 g L−1; bile salts 0.5 g L−1, vitamin K1 10 μL; Tween 80 2 mL (Sigma Aldrich) and sparged with oxygen-free N2 to establish and maintain anaerobic conditions. Stirring was achieved using magnetic stirrers. Test carbohydrates (1% w/v) were added in designated vessels just prior to inoculation with the faecal slurry from a single donor (10% v/v prepared in anaerobic phosphate buffered saline). All tests for a single donor were carried out in parallel. Fermentation temperature was maintained at 37° C. by means of a circulating water bath. Automated pH controllers (Fermac 260; Electrolab UK) kept culture pH within a range of 6.7 and 6.9 by adding 0.5 M NaOH and 0.5 M HCl as required. Fermentations were run for a period of 24 h and samples were withdrawn at 0, 5, 10, and 24 h for organic acid analysis. Table 4 below shows the results of the fermentation runs.
4.05 ± 0.30ab
4.57 ± 0.14ab
1.39 ± 0.07ab
1.95 ± 0.01ab
7.16 ± 0.09d
6.32 ± 0.02cd
0.98 ± 0.01ab
1.35 ± 0.06ab
3.70 ± 2.20abc
0.23 ± 0.01ab
0.69 ± 0.17bcde
1.36 ± 0.01ab
2.89 ± 0.01abcd
7.27 ± 0.00cd
2.18 ± 0.97abc
6.56 ± 0.69bcd
4.86 ± 0.19bc
2.74 ± 0.08ab
3.35 ± 0.03ab
0.26 ± 0.37ab
63.77 ± 14.35cd
59.41 ± 10.96cd
55.29 ± 10.57bc
4.85 ± 0.07cd
9.18 ± 0.10cd
0.53 ± 0.02abcd
1.04 ± 0.05de
5.95 ± 0.02d
4.74 ± 0.03cd
7.24 ± 0.08cd
2.46 ± 2.20ab
3.23 ± 2.17ab
5.93 ± 0.10b
91.12 ± 19.66d
Organic acid (OA) concentrations were determined by gas chromatography equipped with flame ionisation detector (GC-FID) based on the method described by Richardson et al (1989) using 2-ethyl butyric acid as an internal standard. A gas chromatograph analyser (Agilent/HP 6890) equipped with a Flame Ionization Detector (FID) and an HP-5MS column (30 m×0.25 mm) with a 0.25 μm coating (Crosslinked (5%-Phenyl)-methylpolysiloxane, Hewlett Packard, UK) was used for SOFA measurements. Helium was used as carrier gas at a flow rate of 1.7 mL/min (head pressure 133 KPa). Oven initial temperature was set at 63° C., followed by a temperature ramp of 15° C./min to 190° C. and held constant for 3 minutes. A split ratio of 100:1 was used. The appearance of OA in the chromatograms was confirmed based on the retention times of the respective commercial OA standards (Lactic acid, Acetic acid, Propionic acid and Butyric acid) (Sigma-Aldrich, UK)
With reference to
SG-GOS was fermented rapidly as indicated by significant increases in the levels of lactate at 5 and 10 h of fermentation, behaving in a similar manner to the prebiotic control and GOS. Lactate is a fermentation intermediate, that is rapidly utilised through cross-feeding by other members of the gut microbiome. Lactate accumulates in culture when the rate of production is higher compared to the rate of utilisation and it is characteristic of rapid gut microbiome fermentation rates observed during the saccharolysis of oligosaccharides. Acetate, propionate and butyrate concentrations were also significantly higher compared to the negative control and followed similar patterns to those observed by the prebiotic control and GOS.
In the SG-FOS cultures, lactate accumulation was significantly lower compared to SG-GOS was fermented rapidly as was indicated by the accumulation of lactate at 5 and 10 h of fermentation, also observed with the positive control and levels were significantly lower compared to the prebiotic control but very similar to FOS, indicating slower fermentation rates. Acetate, propionate and butyrate concentrations were all significantly higher compared to the negative control and very similar to those in the FOS fermentations but significantly lower to the prebiotic control in terms of acetate formation. In the MV-GOS cultures lactate accumulation was significantly lower compared to GOS and the prebiotic control, indicating less rapid fermentation. Acetate concentrations were significantly higher compared to the negative control and gradually increased over the fermentation period, following similar patterns to the prebiotic control and GOS, albeit at lower levels. MV-GOS significantly increased propionate concentrations, with levels being significantly higher compared to the prebiotic control and GOS. Significant increases in butyrate were observed after 24 h fermentation and were comparable to those with the prebiotic control and GOS.
MV-FOS metabolite formation followed identical patterns to MV-GOS with the exception of butyrate which did not increase significantly.
Overall, the fermentation behaviour of the compounds synthesised shows very close similarities to that of commercially available prebiotics. Their impact on the metabolic activity of the human gut microbiome is characteristic of oligosaccharide saccharolysis. They all increased significantly acetate but also propionate and butyrate, organic acids with important role in cholesterolgenesis, appetite regulation, tight junction integrity and immunomodulation.
The forgoing embodiments are not intended to limit the scope of the protection afforded by the claims, but rather to describe examples of how the invention may be put into practice.
| Number | Date | Country | Kind |
|---|---|---|---|
| 1805578.0 | Apr 2018 | GB | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/GB19/50995 | 4/4/2019 | WO | 00 |
